🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-525628-13-00
Authorised Phase II

“In vivo” biological standardization of the allergenic extracts Dermatophagoides pteronyssinus (DPT) and Dermatophagoides farinae (DF) in patients sensitized to them.

2026-525628-13-00 · tracked via the Priya Life Science EU tracker
Sponsor
Probelte Pharma S.L.
Sponsor type
Pharmaceutical company
Therapeutic area
Disorders of Environmental Origin
Decision date
26/06/2026
Enrollment target
30
Sites
Spain

Condition studied

IgE-mediated respiratory allergic disease due to the allergen whose extract is to be standardized, DPT and DF.

Investigational medicinal product(s)

Solución para prueba con extractos alergénicos DPT 0.1 por punción cutáneaSolución para prueba con extractos alergénicos DF 0.1 por punción cutáneaSolución para prueba con extractos alergénicos DPT 10 por punción cutáneaHISTAMINE DIHYDROCHLORIDESolución para prueba con extractos alergénicos DF 10 por punción cutáneaSolución para prueba con extractos alergénicos DPT 0.01 por punción cutáneaSolución para prueba con extractos alergénicos DPT 1 por punción cutáneaSolución para prueba con extractos alergénicos DF 0.01 por punción cutáneaSolución para prueba con extractos alergénicos DF 1 por punción cutánea

Eligibility

Age group
18-64 years
Sex
Female, Male

Primary endpoint

In vivo determination of the biological activity of the allergenic extracts DPT and DF

Endpoint detail

In vitro biological standardization of DPT and DF allergenic extracts

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525628-13-00 on CTIS ↗ ← All trials in the EU